Tysabri Solution For Injection 300Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Tysabri: Solution for injection (300mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

NATALIZUMAB (na ta LIZ you mab) is used to treat relapsing multiple sclerosis. This drug is not a cure. It is also used to treat Crohn's disease.

In-Depth Information
Select a Medication

Tysabri 300mg/15ml Solution for Injection

NDC: 644060008
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Crohn's Disease, Multiple Sclerosis

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from light
Store in carton until time of use
Protect from freezing
Diluted product must be used within 8 hours
Tysabri 300mg/15ml Solution for Injection

Reported Side Effects for Tysabri 300mg/15ml Solution for Injection

Anaphylactoid Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Brain Deterioration Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Severe Allergy Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Gallstones Incidence:
0.3-1.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
0.6-21.0%*
Severity: MILD
Onset: DELAYED
Thoughts Of Suicide Incidence:
0.6%*
Severity: SEVERE
Onset: DELAYED
Depression Incidence:
1.0-19.0%*
Severity: MODERATE
Onset: DELAYED
Shaking Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Night Sweats Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Dry Skin Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Intestinal Blockage Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
No Menstrual Periods Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Hives Incidence:
2.0%*
Severity: MILD
Onset: RAPID
Weight Loss Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Mouth Ulcers Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Drowsiness Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Menstrual Cramps Incidence:
2.0-6.0%*
Severity: MILD
Onset: DELAYED
Weight Gain Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Cough Incidence:
3.0-7.0%*
Severity: MILD
Onset: DELAYED
Gas Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Constipation Incidence:
4.0%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
4.0%*
Severity: MILD
Onset: RAPID
Uncontrolled Urination Incidence:
4.0%*
Severity: MODERATE
Onset: EARLY
Stomach Pain Incidence:
4.0%*
Severity: MILD
Onset: EARLY
Vaginal Infection Incidence:
4.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Fluid Retention Incidence:
5.0-6.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Cramps Incidence:
5.0%*
Severity: MILD
Onset: DELAYED
Irregular Periods Incidence:
5.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Flu Incidence:
5.0-12.0%*
Severity: MILD
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
6.0-12.0%*
Severity: MILD
Onset: EARLY
Balance Problems Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
8.0%*
Severity: MILD
Onset: DELAYED
Joint Pain Incidence:
8.0-19.0%*
Severity: MILD
Onset: DELAYED
Increased Urination Incidence:
9.0%*
Severity: MILD
Onset: EARLY
Antibody Formation Incidence:
9.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Urinary Urgency Incidence:
9.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
10.0-27.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
10.0%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
12.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
17.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
32.0-38.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More